262 related articles for article (PubMed ID: 38067278)
1. Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
Perrino M; Cordua N; De Vincenzo F; Borea F; Aliprandi M; Cecchi LG; Fazio R; Airoldi M; Santoro A; Zucali PA
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067278
[TBL] [Abstract][Full Text] [Related]
2. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword.
Ballman M; Zhao C; McAdams MJ; Rajan A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565190
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
Zhao C; Rajan A
Mediastinum; 2019 Sep; 3():. PubMed ID: 31608320
[TBL] [Abstract][Full Text] [Related]
5. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor.
Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J
Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721
[TBL] [Abstract][Full Text] [Related]
6. Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.
Perrino M; Voulaz E; Balin S; Cazzato G; Fontana E; Franzese S; Defendi M; De Vincenzo F; Cordua N; Tamma R; Borea F; Aliprandi M; Airoldi M; Cecchi LG; Fazio R; Alloisio M; Marulli G; Santoro A; Di Tommaso L; Ingravallo G; Russo L; Da Rin G; Villa A; Della Bella S; Zucali PA; Mavilio D
Front Immunol; 2024; 15():1288045. PubMed ID: 38629065
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.
Lippner EA; Lewis DB; Robinson WH; Katsumoto TR
Curr Treat Options Oncol; 2019 Jun; 20(7):62. PubMed ID: 31227926
[TBL] [Abstract][Full Text] [Related]
8. Narrative review of immunotherapy in thymic malignancies.
Benitez JC; Besse B
Transl Lung Cancer Res; 2021 Jun; 10(6):3001-3013. PubMed ID: 34295693
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies in thymic epithelial tumors (Review).
Dapergola A; Gomatou G; Trontzas I; Panagiotou E; Dimakakos E; Syrigos N; Kotteas E
Oncol Lett; 2023 Feb; 25(2):84. PubMed ID: 36760515
[TBL] [Abstract][Full Text] [Related]
10. Understanding the landscape of immunotherapy in thymic epithelial tumors.
Maniar R; Loehrer PJ
Cancer; 2023 Apr; 129(8):1162-1172. PubMed ID: 36808725
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions.
Rajan A; Sivapiromrat AK; McAdams MJ
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611047
[TBL] [Abstract][Full Text] [Related]
12. The role of immunotherapy for management of advanced thymic epithelial tumors: a narrative review.
Rajan A; Mullenix C; Shelat M; Zhao C
Mediastinum; 2021 Sep; 5():. PubMed ID: 34541456
[TBL] [Abstract][Full Text] [Related]
13. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.
Girard N; Basse C; Schrock A; Ramkissoon S; Killian K; Ross JS
Oncologist; 2022 Nov; 27(11):919-929. PubMed ID: 35749302
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.
Song X; Fan J; Zhu L; Wang Z; He Y; Zhou C
J Thorac Dis; 2021 Aug; 13(8):5093-5103. PubMed ID: 34527346
[TBL] [Abstract][Full Text] [Related]
16. Balancing the Risk of Adverse Events against the Efficacy of Immunotherapy in Advanced Thymic Epithelial Tumors.
Ohm B; Jungraithmayr W
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612283
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoints in thymic epithelial tumors: challenges and opportunities.
Girard N
Immunooncol Technol; 2019 Oct; 3():8-14. PubMed ID: 35757304
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for thymoma.
Jakopovic M; Bitar L; Seiwerth F; Marusic A; Krpina K; Samarzija M
J Thorac Dis; 2020 Dec; 12(12):7635-7641. PubMed ID: 33447455
[TBL] [Abstract][Full Text] [Related]
19. Update on thymic epithelial tumors: a narrative review.
Cabezón-Gutiérrez L; Pacheco-Barcia V; Carrasco-Valero F; Palka-Kotlowska M; Custodio-Cabello S; Khosravi-Shahi P
Mediastinum; 2024; 8():33. PubMed ID: 38881809
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.
Sun TY; Nguyen B; Chen SB; Natkunam Y; Padda S; van de Rijn M; West R; Neal JW; Wakelee H; Riess JW
JTO Clin Res Rep; 2023 Apr; 4(4):100498. PubMed ID: 37020927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
